tetano
Editor, Senior Moderator
Mol Med. 2012 Jun 19. doi: 10.2119/molmed.2012.00147. [Epub ahead of print]
Novel viral vectored vaccines for the prevention of influenza.
Lambe T.
Source
The Jenner Institute, University of Oxford, Oxford, OX3 7DQ, United Kingdom. <email>Teresa.lambe@ndm.ox.ac.uk</email>
Abstract
Influenza represents a substantial global healthcare burden, with annual epidemics resulting in 3-5 million cases of severe illness with a significant associated mortality. In addition, the risk of a virulent and lethal influenza pandemic has generated widespread and warranted concern. Currently licenced influenza vaccines are limited in their ability to induce efficacious and long-lasting herd immunity. In addition, and as evidenced by the H1N1 pandemic in 2011, there can be a significant delay between the emergence of a pandemic influenza and an effective, antibody-inducing vaccine. There is, therefore, a continued need for new, efficacious vaccines conferring cross-clade protection - obviating the need for biannual reformulation of seasonal influenza vaccines. Development of such a vaccine would yield enormous health benefits to society, but also greatly reduce the associated global healthcare burden. There are a number of alternative influenza vaccine technologies being assessed both pre-clinically and clinically. In this review we discuss viral vectored vaccines, either recombinant live-attenuated or replication-deficient viruses; which are current lead candidates inducing efficacious and long-lasting immunity toward influenza viruses. These alternate influenza vaccines offer real promise to deliver viable alternatives to currently deployed vaccines and more importantly may confer long-lasting and universal protection against influenza viral infection.
PMID:
22735755
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22735755
Novel viral vectored vaccines for the prevention of influenza.
Lambe T.
Source
The Jenner Institute, University of Oxford, Oxford, OX3 7DQ, United Kingdom. <email>Teresa.lambe@ndm.ox.ac.uk</email>
Abstract
Influenza represents a substantial global healthcare burden, with annual epidemics resulting in 3-5 million cases of severe illness with a significant associated mortality. In addition, the risk of a virulent and lethal influenza pandemic has generated widespread and warranted concern. Currently licenced influenza vaccines are limited in their ability to induce efficacious and long-lasting herd immunity. In addition, and as evidenced by the H1N1 pandemic in 2011, there can be a significant delay between the emergence of a pandemic influenza and an effective, antibody-inducing vaccine. There is, therefore, a continued need for new, efficacious vaccines conferring cross-clade protection - obviating the need for biannual reformulation of seasonal influenza vaccines. Development of such a vaccine would yield enormous health benefits to society, but also greatly reduce the associated global healthcare burden. There are a number of alternative influenza vaccine technologies being assessed both pre-clinically and clinically. In this review we discuss viral vectored vaccines, either recombinant live-attenuated or replication-deficient viruses; which are current lead candidates inducing efficacious and long-lasting immunity toward influenza viruses. These alternate influenza vaccines offer real promise to deliver viable alternatives to currently deployed vaccines and more importantly may confer long-lasting and universal protection against influenza viral infection.
PMID:
22735755
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22735755